Telomir Pharmaceuticals (Telomir Pharmaceuticals) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Days Payable?

Telomir Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2024 was $0.59 Mil. Telomir Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Telomir Pharmaceuticals's Days Payable or its related term are showing as below:

TELO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

Telomir Pharmaceuticals's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Telomir Pharmaceuticals Days Payable Historical Data

The historical data trend for Telomir Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Days Payable Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Telomir Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Telomir Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Days Payable falls into.

Telomir Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Telomir Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.404	+	0.707)	/	2 )	/	0	*	365
=	0.5555					/	0	*	365
=	N/A

Telomir Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0.707	+	0.479)	/	2 )	/	0	*	365 / 4
=	0.593					/	0	*	365 / 4
=	N/A

Telomir Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024